Leuven,
Lytham Partners Fall 2021Investor Conference , October 5-7, 2021. Pre-recorded CEO Presentation available starting onOctober 5 at10:15 AM ET .
For more information, please visit Oxurion’s events page:
www.oxurion.com/news-events#view-conferences_events-page
END
For further information please contact:
Chief Executive Officer Tel: +32 16 75 13 10 tom.graney@oxurion.com Chief Corporate Development Tel: +32 479 783583 Michael.dillen@oxurion.com | EU Tel: +44 20 7638 9571 oxurion@medistrava.com US Westwicke, an Tel: +1 617 835 9304 chris.brinzey@westwicke.com |
About
- THR-687 is a highly selective pan-RGD integrin antagonist that is initially being developed as a potential first line therapy for DME patients. Positive topline results in a Phase 1 clinical study assessing THR-687 as a treatment for DME were announced in 2020.
Oxurion is currently conducting a Phase 2 clinical trial (“INTEGRAL”) evaluating THR-687 in patients with DME. THR-687 also has the potential to deliver improved treatment outcomes for patients with wet AMD and RVO. - THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the 40-50% of DME patients showing suboptimal response to anti-VEGF therapy. THR-149 has shown positive topline Phase 1 results for the treatment of DME. The company is currently conducting a Phase 2 clinical trial (“KALAHARI”) evaluating multiple injections of THR-149 in DME patients previously showing a suboptimal response to anti-VEGF therapy. Following positive data from Part A of this Phase 2 study (dose selection), the Company has initiated Part B of the study.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of
Source:
2021 GlobeNewswire, Inc., source